This article is freely available to all

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Amisulpride is a second-generation antipsychotic approvedas monotherapy for treatment of refractory schizophrenia.1 It acts with a unique pharmacologic profile that haspreferential affinity for D2/D3 receptors and specificity forlimbic rather than striatal structures. Very few side effects ofamisulpride therapy, and none with a dermatologic nature, havebeen reported.2